Avidity Biosciences was officially founded in 2012 by a team of visionary scientists and entrepreneurs aiming to pioneer a transformative new class of targeted RNA therapeutics known as antibody-oligonucleotide conjugates. Headquartered originally in San Diego, California, the company focused its early research on overcoming traditional delivery barriers associated with oligonucleotide therapies, ultimately evolving into a publicly traded clinical-stage biopharmaceutical leader before its recent acquisition.